

Research article

Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma

Zorica Juranic*¹, Jelena Radic¹, Aleksandra Konic-Ristic², Svetislav Jelic¹, Biljana Mihaljevic³, Ivan Stankovic², Suzana Matkovic¹, Irina Besu¹ and Dušica Gavrilović¹

Address: ¹Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia, ²Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia and ³School of Medicine, University of Belgrade, Belgrade, Serbia

Email: Zorica Juranic* - juranicz@ncrc.ac.yu; Jelena Radic - jelradi@sbb.yu; Aleksandra Konic-Ristic - sandrakonicristic@yahoo.com; Svetislav Jelic - jelics@ncrc.ac.yu; Biljana Mihaljevic - bimih@eunet.yu; Ivan Stankovic - istank@eunet.yu; Suzana Matkovic - matkovic@yubc.net; Irina Besu - irina.besu@ncrc.ac.yu; Dušica Gavrilović - duca@ncrc.ac.yu

* Corresponding author

Published: 28 May 2008

Received: 26 March 2008

BMC Immunology 2008, 9:22 doi:10.1186/1471-2172-9-22

Accepted: 28 May 2008

This article is available from: <http://www.biomedcentral.com/1471-2172/9/22>

© 2008 Juranic et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Multiple myeloma (MM) is a clonal B-cell disorder with many immunological disturbances. The aim of this work was to assess whether some of food antigens contribute to the imbalance of immune response by screening the sera of MM patients for their immunoreactivity to food constituent gliadin, to tissue transglutaminase-2 (tTG-2) and to Ro/SSA antigen.

Sera from 61 patients with MM in various stages of disease, before, or after some cycles of conventional therapy were analyzed by commercial Binding Site ELISA tests. The control group consisted of 50 healthy volunteers. Statistical analysis of data obtained was performed by Mann Whitney Test.

Results: The higher serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one of control people. The enhanced serum IgG immunoreactivity to gliadin was found in only two of tested patients and in two controls. The enhanced IgA immunoreactivity to tTG-2 was found in 10/49 patients' sera, while 4/45 patients had higher serum IgG immunoreactivity. The enhanced serum IgG immunoreactivity to RoSSA antigen was found in 9/47 analyzed MM patients' sera. Statistical analysis of data obtained revealed that only the levels of anti-tTG-2 IgA immunoreactivity in patients with MM were significantly higher than these obtained in healthy controls ($P < 0.02$)

Conclusion: Data obtained showed the existence of the enhanced serum immunoreactivity to gliadin, tTG-2 and Ro/SSA antigens in some patients with MM. These at least partially could contribute to the immunological imbalance frequently found in this disease.

Background

Multiple myeloma (MM) is a clonal B-cell disorder which diagnosis comprise the examination of bone marrow for plasma cell infiltration, detection and quantification of monoclonal protein "M" component in the serum or urine, and evidence of end-organ damage (hypercalcemia, renal insufficiency, anemia or bone lesions). Many of the laboratory parameters contribute to myeloma diagnosis due to plenty of immunological disturbances [1]. It was shown that the antibodies contained in M component have various specificity to: some proteins, double-stranded DNA, several antibiotics [2], and sometimes to gliadin (and/or calreticulin?) [3].

As the enhanced levels of the serum antibodies to gliadin are found in patients with celiac disease, as well as of antibodies to transglutaminase-2 (TTG-2) [4,5], to calreticulin [6,7] and Ro/SSA antigen [8], the aim of this work was the screening of MM patients' sera for their immunoreactivity to food constituent gliadin, and to autoantigens: tissue transglutaminase-2 (tTG-2) and Ro/SSA antigen, in order to assess whether immunoreactivity to mentioned antigens at least partially contributes to the immunological imbalance in multiple myeloma.

Methods

Patients

Sera from 61 patients with MM in various stages of disease, before or after some cycles of conventional therapy, were analyzed for immunity to gliadin, tissue TTG-2, and Ro/SSA antigen. Determination of serum IgA and IgG immunoreactivity to gliadin (IU/ml), to tTG-2 (IU/ml), or to Ro/SSA (IU/ml), was done by diagnostic, commercial ELISA (Binding Site) tests. Briefly, 100 µl of diluted (1:100) human sera, commercial controls and calibrators were dispensed in appropriate wells of the plates provided in the kit. During the first incubation, autoantibodies recognizing the antigen bind to it and all unbound proteins were removed by washings. After that, purified peroxidase labeled rabbit anti human IgA or IgG conjugate (100 µl) which binds to the captured human autoantibodies was added, and the excess unbound conjugate is removed by washings. The conjugate was treated with TMB (3,3,5,5-tetramethylbenzidine). The reaction was stopped by the addition of phosphoric acid. The concentration of autoantibodies was measured on ELISA reader at 450 nm. Cut offs for each test was evaluated as the mean X+2 SD.

The control group consisted of 50 healthy volunteers (age range was 27–58 years, 26 were female).

Statistical analysis of data obtained was performed by Mann Whitney Test.

Experimental research that is reported in the manuscript has been performed with the approval of the ethics committee of Institute of Oncology and Radiology of Serbia.

Results

Cut off values of anti-gliadin reactivity obtained analyzing 50 healthy sera were 3.46 IU/ml for IgA and 5.83 IU/ml for IgG.

The elevated serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one of controls. From these patients, 4 were with IgA myeloma and 4 were with IgG myeloma, while 6 were without M component in their sera.

Statistical analysis of data obtained revealed that the level of anti-gliadin IgA immunoreactivity for patients with MM was not significantly differ than that for controls (P = 0.052).

Surprisingly, the elevated IgG immunoreactivity to gliadin was found only in two of tested MM patients sera and in two of control people (Fig 1.) and both patients were with IgG myeloma.




Figure 1
The anti-gliadin serum IgA and IgG immunoreactivity of healthy controls and of patients with myeloma.

Cut off values of anti-tTg reactivity obtained analyzing 50 healthy sera were 1.86 IU/ml for IgA and 6.17 IU/ml for IgG.

As seen on Fig. 2.a. higher than cut off of IgA immunoreactivity to tTg was found in 10/49 patients and 2 of controls. From 10 anti-tTg IgA positive patients 4 were with IgA and 4 were with IgG myeloma, while 2 were without M component in their sera. Statistical analysis of data obtained revealed that the level of anti-tTG-2 IgA immunoreactivity in patients with myeloma was significantly higher than that obtained in healthy controls ($P < 0.02$).

Sera from 4/45 patients and 3 controls had higher than cut off value for IgG immunoreactivity (Fig. 2.b). All 4 anti-tTg IgG positive patients were with IgG MM.




Figure 2
The anti tTG serum IgA and IgG immunoreactivity of healthy controls and of patients with myeloma.




Figure 3
The anti-Ro/SSA serum IgG immunoreactivity of healthy controls and of patients with myeloma.

Cut off values of anti-Ro/SSA IgG reactivity obtained analyzing 50 healthy sera was 3.59 IU/ml. The enhanced IgG immunoreactivity to RoSSA antigen found in this work in 9/47 analyzed MM patients' sera (Fig. 3). These anti-RoSSA IgG positive patients were: 2 with IgA, 5 with IgG, and 2 without M component.

Discussion

In this work, the immunoreactivity to one of the food constituents is found in some MM patients. It is manifested through the enhanced levels of serum IgA immunoreactivity to gliadin. Data obtained by ELISA tests indicate that especially anti-gliadin, IgA immunity is developed in patients with MM. It seems that the elevated immunoreactivities to gliadin could not be the consequence of overproduction of immunoglobulins from M component, because the enhanced antigliadin IgA immunoreactivity was found in the serum of some of MM patients without M component as well as in patients with IgG myeloma too. It is also possible that in some patients serum antigliadin immunoreactivities could be hidden in immune complexes in circulation (CIC) and in these cases this reactivity could not be revealed by ELISA test. One of the solutions for this problem could be the electrophoresis of serum proteins performed in the alkaline conditions pH = 8.6 i.e., in conditions which enables dissociation of antibodies from antigen in CIC [9,10]; these antibodies physically separated from the gliadin by electrophoresis could then again react with gliadin (0.2%, or 0.4% in 0.5% SDS) in the test for immunofixation [3].

It must be mentioned that only the level of anti tTG-2 IgA immunoreactivity in patients with myeloma was signifi-

cantly higher than these obtained in healthy controls. Besides, our results show that autoimmune determinants as the enhanced immunity to tTG-2, and to Ro/SSA antigen, which are present in patients with gluten intolerance [4,5] and autoimmune diseases [8] respectively, are present in some patients with MM, too.

Immunoreactivity to some of these antigens was also found in few of healthy controls, indicating that the immunoreactivities to tTG or to Ro/SSA antigens, or to gliadin are not strictly specific for MM, but that they are only one part of the complex immunological disturbances found in this disease. Findings from this work are in accordance with the previously published reports [11-14] pointing to the partial immunological similarity between MM and celiac disease.

This work indicates that gliadin as food antigen could at least partially contribute to the plethora of immunological disturbances in some patients with MM. Due to the aminoacid sequence equality or high homology between α -gliadin and γ -gliadin and *C albicans*-hyphal wall protein 1 (HWP1), and with calreticulin, it is also possible that the determined immunoreactivity with gliadin is in part the consequence of the cross reactivity with mentioned proteins [15].

Conclusion

Data from this work showed the existence of the enhanced serum immunoreactivity to gliadin, tTG-2 and Ro/SSA antigens in some patients with MM and set up the question whether MM is also on the list of malignant diseases which are associated with immunological aspect of gluten intolerance [16-19]. They call for the additional research to elucidate the clinical importance of both: the elevated humoral immunity to food antigens and to some autoantigens in patients with MM.

Authors' contributions

ZJ designed the study, interpreted the data and wrote the manuscript. AK-R and IB have done the ELISA blood testing, collected the data, and organized the database, while DG performed the statistical analysis. SJ, SM and BM enrolled the patients with myeloma, revised critically the manuscript and added important points to the discussion, JR have done determination of the type of heavy and light immunoglobulin chains presented in the M component in the serum, by immunofixation. IS helped with ELISA serum testing. All authors approved the final draft of the manuscript.

Acknowledgements

This work was financed by Ministry of Science and Environmental Protection of Serbia grant numbers 145006 and 145055. Authors express their gratitude to Ljiljana Vuckovic-Dekic for editing the manuscript.

References

1. Dispenzieri A, Kyle RA: **Multiple myeloma: clinical features and indications for therapy.** *Best Pract Res Clin Haematol* 2005, **18**:553-568.
2. Merlini G, Farhangi M, Osserman EF: **Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias.** *Semin Oncol* 1986, **13**:350-365.
3. Juranic Z, Radic J, Konic-Ristic A, Jelic S, Mihaljevic B, Besu I: **Antibodies contained in "M" component of some patients with multiple myeloma are directed to food antigens?** *Leuk Res* :1585-1586. 2006; Mar 3
4. Troncone R, Maurano F, Rossi M, Micillo M, Greco L, Auricchio R, Salerno G, Salvatore F, Sacchetti L: **IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease.** *J Pediatr* 1999, **134**:166-171.
5. Tiberti C, Bonamico M, Dotta F, Verrienti A, Di Tola M, Liu E, Ferri M, Nenna R, Picarelli A, Eisenbarth GS: **Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: A new tool to distinguish disease-specific immunoreactivities.** *Clin Immunol* . Available online 23 June 2006
6. Sanchez DL, Tuckova L, Sebo P, Michalak M, Whelan A, Sterzl I, Jelinkova L, Havrdova E, Imramovska M, Benes Z, Krupickova S, Tlaskalova-Hogenova H: **Occurrence of IgA and IgG Autoantibodies to calreticulin in Coeliac Disease and Various Autoimmune Diseases.** *J Autoimmun* 2000, **15**:441-449.
7. Malhotra R: **Collectin receptor (C1q receptor): structure and function.** *Behring Inst Mitt* 1993, **93**:254-61.
8. Bonaci-Nikolic B, Andrejevic S, Radlovic N, Davidovic I, Sofronic L, Suran M, Micev M, Nikolic MM: **Serological and clinical comparison of children and adults with anti-endomysial antibodies.** *J Clin Immunol* 2007, **27**(2):163-71. Epub 2007 Jan 23.
9. Schutzer SE, Coyle PK, Reid P, Holland B: **Borrelia burgdorferi-specific immune complexes in acute Lyme disease.** *JAMA* 2000, **284**:695-696.
10. Brunner M, Sigal LH: **Use of serum immune complexes in a new test that accurately confirms early Lyme disease and active infection with Borrelia burgdorferi.** *J Clin Microbiol* 2001:3213-3221.
11. Street ME, Volta C, Ziveri MA, Zanacca C, Banchini G, Viani I, Rossi M, Virdis R, Bernasconi S: **Changes and relationships of IGFS and IGFBS and cytokines in coeliac disease at diagnosis and on gluten-free diet.** *Clin Endocrinol (Oxf)* . 2007 Aug 6
12. Ebert EC: **IL-15 converts human intestinal intraepithelial lymphocytes to CD94 producers of IFN-gamma and IL-10, the latter promoting Fas ligand-mediated cytotoxicity.** *Immunology* 2005, **115**(1):118-26.
13. Sfiridaki A, Miyakis S, Tsirakis G, Alegakis A, Passam AM, Kandidaki E, Margioris AN, Alexandrakis MG: **Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease.** *Clin Chem Lab Med* 2005, **43**(9):934-8.
14. Pappa C, Miyakis S, Tsirakis G, Sfiridaki A, Alegakis A, Kafousi M, Stathopoulos EN, Alexandrakis MG: **Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma.** *Cytokine* 2007, **37**(2):171-5.
15. Nieuwenhuizen WF, Pieters RH, Knippels LM, Jansen MC, Koppelman SJ: **Is Candida albicans a trigger in the onset of coeliac disease?** *Lancet* **361**(9375):2152-4. 2003 Jun 21
16. Cellier C, Delabesse E, Helmer C, Patey N, Matuchansky C, Jabri B, Macintyre E, Cerf-Bensussan N, Brousse N: **Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma.** *Lancet* 2000, **356**:203-208.
17. Catassi C, Fabiani E, Corrao G, Barbato M, De Renzo A, Carella AM, Gabrielli A, Leoni P, Carroccio A, Baldassarre M, Bertolani P, Caramaschi P, Sozzi M, Guariso G, Volta U, Corazza GR: **Risk of non-Hodgkin lymphoma in coeliac disease.** *JAMA* 2000, **287**:1413-1419.
18. Van Overbeke L, Ectors N, Tack J: **What is the role of celiac disease in enteropathy-type intestinal lymphoma? A retrospective study of nine cases.** *Acta Gastroenterol Belg* 2005, **68**:419-423.
19. Brousse N, Meijer JW: **Malignant complications of coeliac disease.** *Best Pract Res Clin Gastroenterol* 2005, **19**:401-412.

20. Silano M, Volta U, Mecchia AM, Dessi M, Di Benedetto R, De Vincenzi M: **Collaborating centers of the Italian registry of the complications of coeliac disease. Delayed diagnosis of coeliac disease increases cancer risk.** *BMC Gastroenterol* 7:8. 2007 Mar 9

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

